The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Primary Central Nervous System Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred Radiotherapy
Abstract
Purpose: To evaluate response rate, response duration, overall survival (OS), and toxicity in primary CNS lymphoma (PCNSL) after systemic and intraventricular chemotherapy with deferred radiotherapy. Patients and Methods: From September 1995 to July 2001, 65 consecutive patients with PCNSL (median age, 62 years) were enrolled onto a pilot and phase II study evaluating chemotherapy without radiotherapy. A high-dose methotrexate (MTX; cycles 1, 2, 4, and 5) and cytarabine (ARA-C; cycles 3 and 6)–based systemic therapy (including dexamethasone, vinca-alkaloids, ifosfamide, and cyclophosphamide) was combined with intraventricular MTX, prednisolone, and ARA-C. Results: Sixty-one of 65 patients were assessable for response. Of these, 37 patients (61%) achieved complete response, six (10%) achieved partial response, and 12 (19%) progressed under therapy. Six (9%) of 65 patients died because of treatment-related complications. Follow-up is 0 to 87 months (median, 26 months). The Kaplan-Meier estimates for median time to treatment failure (TTF) and median OS were 21 months and 50 months, respectively. For patients older than 60 years, median survival was 34 months, and the median TTF was 15 months. In patients younger than 61 years, median survival and median TTF have not been reached yet; the 5-year survival fraction is 75%. Systemic toxicity was mainly hematologic. Ommaya reservoir infection occurred in 12 patients (19%), and permanent cognitive dysfunction possibly as a result of treatment occurred in only two patients (3%). Conclusion: Primary chemotherapy based on high-dose MTX and ARA-C is highly efficient in PCNSL. Response rate and response duration in this series are comparable to the response rates and durations reported after combined radiotherapy and chemotherapy. Neurotoxicity was infrequent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Harris, N., Jaffe, E., Stein, H., Banks, P., Chan, J., Cleary, M., Delsol, G., De Wolf- Peeters, C., Falini, B., & Gatter, K. (1994) · Blood · doi:10.1182/blood.v84.5.1361.1361 · Cited by 6,327
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
DeAngelis, L. M., Seiferheld, W., Schold, S. C., Fisher, B., & Schultz, C. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.013 · Cited by 738
Nelson, D. F., Martz, K. L., Bonner, H., Nelson, J. S., Newall, J., Kerman, H. D., Thomson, J. W., & Murray, K. J. (1992) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(92)90538-s · Cited by 635
Treatment for Primary CNS Lymphoma: The Next Step
Abrey, L. E., Yahalom, J., & DeAngelis, L. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3144 · Cited by 607
Long-term survival in primary CNS lymphoma.
Abrey, L. E., DeAngelis, L. M., & Yahalom, J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.859 · Cited by 577
Batchelor, T., Carson, K., O’Neill, A., Grossman, S. A., Alavi, J., New, P., Hochberg, F., & Priet, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.036 · Cited by 546
Combined modality therapy for primary CNS lymphoma.
DeAngelis, L. M., Yahalom, J., Thaler, H. T., & Kher, U. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.635 · Cited by 544
Harris, N. L. (1995) · Current Diagnostic Pathology · doi:10.1016/s0968-6053(00)80051-4 · Cited by 527
Soussain, C., Suzan, F., Hoang-Xuan, K., Cassoux, N., Levy, V., Azar, N., Belanger, C., Achour, E., Ribrag, V., Gerber, S., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.742 · Cited by 322
McAllister, L. D., Doolittle, N. D., Guastadisegni, P. E., Kraemer, D. F., Lacy, C. A., Crossen, J. R., & Neuwelt, E. A. (2000) · Neurosurgery · doi:10.1093/neurosurgery/46.1.51 · Cited by 239
Is Intrathecal Methotrexate Necessary in the Treatment of Primary CNS Lymphoma?
Khan, R. B., Shi, W., Thaler, H. T., DeAngelis, L. M., & Abrey, L. E. (2002) · Journal of Neuro-Oncology · doi:10.1023/a:1016077907952 · Cited by 186
Herrlinger, U., Schabet, M., Brugger, W., Kortmann, R., Küker, W., Deckert, M., Engel, C., Schmeck‐Lindenau, H., Mergenthaler, H., Krauseneck, P., et al. (2002) · Annals of Neurology · doi:10.1002/ana.10102 · Cited by 180
Self-citationGuha-Thakurta, N., Damek, D., Pollack, C., & Hochberg, F. H. (1999) · Journal of Neuro-Oncology · doi:10.1023/a:1006210703827 · Cited by 159
Hiraga, S., Arita, N., Ohnishi, T., Kohmura, E., Yamamoto, K., Oku, Y., Taki, T., Sato, M., Aozasa, K., & Yoshimine, T. (1999) · Journal of Neurosurgery · doi:10.3171/jns.1999.91.2.0221 · Cited by 158
CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin’s lymphoma
Bessell, E. M., Graus, F., López‐Guillermo, A., Villà, S., Verger, E., Petit, J., Holland, I. M., & Byrne, P. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01451-1 · Cited by 93
Fließbach, K., Urbach, H., Helmstaedter, C., Pels, H., Glasmacher, A. G., Kraus, J. A., Klockgether, T., Schmidt‐Wolf, I. G. H., & Schlegel, U. S. (2003) · Archives of Neurology · doi:10.1001/archneur.60.4.563 · Cited by 73
Self-citationCombined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study
Schlegel, U. S. (2001) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.71.1.118 · Cited by 62
Self-citation
Cited by
Abrey, L. E., Batchelor, T. T., Ferreri, A. J. M., Gospodarowicz, M., Pulczynski, E. J., Zucca, E., Smith, J. R., Korfel, A., Soussain, C., DeAngelis, L. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.524 · Cited by 914
Ferreri, A. J., Reni, M., Foppoli, M., Martelli, M., Pangalis, G. A., Frezzato, M., Cabras, M. G., Fabbri, A., Corazzelli, G., Ilariucci, F., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61416-1 · Cited by 662
Morris, P. G., Correa, D. D., Yahalom, J., Raizer, J. J., Schiff, D., Grant, B., Grimm, S., Lai, R. K., Reiner, A. S., Panageas, K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.4910 · Cited by 500
Hoang-Xuan, K., Bessell, E., Bromberg, J., Hottinger, A. F., Preusser, M., Rudà, R., Schlegel, U., Siegal, T., Soussain, C., Abacioglu, U., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00076-5 · Cited by 411
Self-citationCNS complications of radiotherapy and chemotherapy
Soussain, C., Ricard, D., Fike, J. R., Mazeron, J.-J., Psimaras, D., & Delattre, J.-Y. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61299-x · Cited by 410
Metadata
- Authors
- Pels, H., Schmidt-Wolf, I. G. H., Glasmacher, A., Schulz, H., Engert, A., Diehl, V., Zellner, A., Schackert, G., Reichmann, H., Kroschinsky, F., Vogt-Schaden, M., Egerer, G., Bode, U., Schaller, C., Deckert, M., Fimmers, R., Helmstaedter, C., Atasoy, A., Klockgether, T., & Schlegel, U.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-12-15
- Volume
- 21
- Issue
- 24
- Pages
- 4489-4495
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2099015738
- Cited by
- 427
- References
- 21
- FWCI
- 16.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.